| Followers | 200 |
| Posts | 25597 |
| Boards Moderated | 0 |
| Alias Born | 04/03/2010 |
Thursday, August 04, 2022 2:47:45 PM
Not by any objective measure, and you may not have understood how to manage the risk in a start-up bio at the beginning, or managed that risk well. That is a difficult thing, I realize. But not by any measure any more than two people investing in an Apple, despite it being a successful company can have entirely different results in their account. One can do well, another can even lose money on a gaining stock if they don’t know what they are doing.
These stocks are volatile. I am not a licensed advisor, this is just my own experience, but you never invest all at once or early. If you buy early, you buy against a portfolio of other stocks and you manage your price. That is just the nature of microcap bios.
If you bought day one in any bio, unless you sold right away and bought again slowly later, I’d say generally, with drugs still in trials and development, you’ll only do well on an early buyout or partnership, but also again, only if you maintained an average price closer to the lows of that stock than buying at the highs. So you accumulate slowly. Never chase and don’t buy out of fomo.
I don’t know the full story of your buys, but your story is not everyone’s story nor is it really the only or main story of investing NWBO.
These stocks are volatile. I am not a licensed advisor, this is just my own experience, but you never invest all at once or early. If you buy early, you buy against a portfolio of other stocks and you manage your price. That is just the nature of microcap bios.
If you bought day one in any bio, unless you sold right away and bought again slowly later, I’d say generally, with drugs still in trials and development, you’ll only do well on an early buyout or partnership, but also again, only if you maintained an average price closer to the lows of that stock than buying at the highs. So you accumulate slowly. Never chase and don’t buy out of fomo.
I don’t know the full story of your buys, but your story is not everyone’s story nor is it really the only or main story of investing NWBO.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
